Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights Over 250 patient start forms received by the end of the first quarter – – Cash and cash equivalents, and investments of $360.9 million at March 31, 2021 – – Conference call to be hosted today at 5:00 p.m. ET – Aurinia Pharmaceuticals Inc. today issued its financial results for the first quarter ended March 31, 2021. Amounts, unless specified otherwise, are expressed in U.S. dollars. “2021 started with the FDA … – Over 250 patient start forms received by the end of the first quarter – – Cash and cash equivalents, and investments of $360.9 million at March 31, 2021 – – Conference call to be hosted today at 5:00 p.m. ET –